139 related articles for article (PubMed ID: 12538811)
41. Pharmacokinetics of saquinavir hard-gel/ritonavir and atazanavir when combined once daily in HIV Type 1-infected individuals administered different atazanavir doses.
Boffito M; Maitland D; Dickinson L; Back D; Hill A; Fletcher C; Moyle G; Nelson M; Gazzard B; Pozniak A
AIDS Res Hum Retroviruses; 2006 Aug; 22(8):749-56. PubMed ID: 16910830
[TBL] [Abstract][Full Text] [Related]
42. In vivo evaluation of P-glycoprotein and breast cancer resistance protein modulation in the brain using [(11)C]gefitinib.
Kawamura K; Yamasaki T; Yui J; Hatori A; Konno F; Kumata K; Irie T; Fukumura T; Suzuki K; Kanno I; Zhang MR
Nucl Med Biol; 2009 Apr; 36(3):239-46. PubMed ID: 19324269
[TBL] [Abstract][Full Text] [Related]
43. Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis.
Ribera E; Azuaje C; Lopez RM; Domingo P; Curran A; Feijoo M; Pou L; Sánchez P; Sambeat MA; Colomer J; Lopez-Colomes JL; Crespo M; Falcó V; Ocaña I; Pahissa A
J Antimicrob Chemother; 2007 Apr; 59(4):690-7. PubMed ID: 17307771
[TBL] [Abstract][Full Text] [Related]
44. Effect of efflux inhibition on brain uptake of itraconazole in mice infected with Cryptococcus neoformans.
Imbert F; Jardin M; Fernandez C; Gantier JC; Dromer F; Baron G; Mentre F; Van Beijsterveldt L; Singlas E; Gimenez F
Drug Metab Dispos; 2003 Mar; 31(3):319-25. PubMed ID: 12584159
[TBL] [Abstract][Full Text] [Related]
45. The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model.
Doran A; Obach RS; Smith BJ; Hosea NA; Becker S; Callegari E; Chen C; Chen X; Choo E; Cianfrogna J; Cox LM; Gibbs JP; Gibbs MA; Hatch H; Hop CE; Kasman IN; Laperle J; Liu J; Liu X; Logman M; Maclin D; Nedza FM; Nelson F; Olson E; Rahematpura S; Raunig D; Rogers S; Schmidt K; Spracklin DK; Szewc M; Troutman M; Tseng E; Tu M; Van Deusen JW; Venkatakrishnan K; Walens G; Wang EQ; Wong D; Yasgar AS; Zhang C
Drug Metab Dispos; 2005 Jan; 33(1):165-74. PubMed ID: 15502009
[TBL] [Abstract][Full Text] [Related]
46. Analysis of the pharmacokinetic boosting effects of ritonavir on oral bioavailability of drugs in mice.
Tomaru A; Takeda-Morishita M; Banba H; Takayama K
Drug Metab Pharmacokinet; 2013; 28(2):144-52. PubMed ID: 22971642
[TBL] [Abstract][Full Text] [Related]
47. Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adults.
Ribera E; Lopez RM; Diaz M; Pou L; Ruiz L; Falcó V; Crespo M; Azuaje C; Ruiz I; Ocaña I; Clotet B; Pahissa A
Antimicrob Agents Chemother; 2004 Nov; 48(11):4256-62. PubMed ID: 15504850
[TBL] [Abstract][Full Text] [Related]
48. P-glycoprotein and mutlidrug resistance-associated proteins limit the brain uptake of saquinavir in mice.
Park S; Sinko PJ
J Pharmacol Exp Ther; 2005 Mar; 312(3):1249-56. PubMed ID: 15528451
[TBL] [Abstract][Full Text] [Related]
49. Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycoprotein.
Sparreboom A; Planting AS; Jewell RC; van der Burg ME; van der Gaast A; de Bruijn P; Loos WJ; Nooter K; Chandler LH; Paul EM; Wissel PS; Verweij J
Anticancer Drugs; 1999 Sep; 10(8):719-28. PubMed ID: 10573204
[TBL] [Abstract][Full Text] [Related]
50. Evaluation of the P-glycoprotein- and breast cancer resistance protein-mediated brain penetration of 11C-labeled topotecan using small-animal positron emission tomography.
Yamasaki T; Fujinaga M; Kawamura K; Hatori A; Yui J; Nengaki N; Ogawa M; Yoshida Y; Wakizaka H; Yanamoto K; Fukumura T; Zhang MR
Nucl Med Biol; 2011 Jul; 38(5):707-14. PubMed ID: 21718946
[TBL] [Abstract][Full Text] [Related]
51. Enhanced antinociception of the model opioid peptide [D-penicillamine] enkephalin by P-glycoprotein modulation.
Chen C; Pollack GM
Pharm Res; 1999 Feb; 16(2):296-301. PubMed ID: 10100317
[TBL] [Abstract][Full Text] [Related]
52. HIV protease inhibitor ritonavir: a more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833.
Drewe J; Gutmann H; Fricker G; Török M; Beglinger C; Huwyler J
Biochem Pharmacol; 1999 May; 57(10):1147-52. PubMed ID: 11230802
[TBL] [Abstract][Full Text] [Related]
53. Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein.
Bardelmeijer HA; Beijnen JH; Brouwer KR; Rosing H; Nooijen WJ; Schellens JH; van Tellingen O
Clin Cancer Res; 2000 Nov; 6(11):4416-21. PubMed ID: 11106262
[TBL] [Abstract][Full Text] [Related]
54. Lack of interaction between enfuvirtide and ritonavir or ritonavir-boosted saquinavir in HIV-1-infected patients.
Ruxrungtham K; Boyd M; Bellibas SE; Zhang X; Dorr A; Kolis S; Kinchelow T; Buss N; Patel IH
J Clin Pharmacol; 2004 Jul; 44(7):793-803. PubMed ID: 15199084
[TBL] [Abstract][Full Text] [Related]
55. Effect of a modified saquinavir/ritonavir dosing regimen with lower dose lead-in phase on QTc interval, pharmacokinetics, antiviral activity and safety in treatment-naïve HIV-1-infected patients.
Boffito M; Jackson A; Pozniak A; Giraudon M; Kulkarni R; Abelardo MC; Patel IH; Morcos PN
Drugs R D; 2015 Mar; 15(1):141-53. PubMed ID: 25742730
[TBL] [Abstract][Full Text] [Related]
56. Abcg2/Bcrp1 mediates the polarized transport of antiretroviral nucleosides abacavir and zidovudine.
Pan G; Giri N; Elmquist WF
Drug Metab Dispos; 2007 Jul; 35(7):1165-73. PubMed ID: 17437964
[TBL] [Abstract][Full Text] [Related]
57. Effect of saquinavir/ritonavir (1000/100 mg bid) on the pharmacokinetics of methadone in opiate-dependent HIV-negative patients on stable methadone maintenance therapy.
Jamois C; Smith P; Morrison R; Riek M; Patel A; Schmitt C; Morcos PN; Zhang X
Addict Biol; 2009 Jul; 14(3):321-7. PubMed ID: 19523046
[TBL] [Abstract][Full Text] [Related]
58. Oral coadministration of elacridar and ritonavir enhances brain accumulation and oral availability of the novel ALK/ROS1 inhibitor lorlatinib.
Li W; Sparidans RW; Wang Y; Lebre MC; Beijnen JH; Schinkel AH
Eur J Pharm Biopharm; 2019 Mar; 136():120-130. PubMed ID: 30660696
[TBL] [Abstract][Full Text] [Related]
59. Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir.
Hsu A; Granneman GR; Cao G; Carothers L; el-Shourbagy T; Baroldi P; Erdman K; Brown F; Sun E; Leonard JM
Clin Pharmacol Ther; 1998 Apr; 63(4):453-64. PubMed ID: 9585800
[TBL] [Abstract][Full Text] [Related]
60. Investigation of efflux transport of dehydroepiandrosterone sulfate and mitoxantrone at the mouse blood-brain barrier: a minor role of breast cancer resistance protein.
Lee YJ; Kusuhara H; Jonker JW; Schinkel AH; Sugiyama Y
J Pharmacol Exp Ther; 2005 Jan; 312(1):44-52. PubMed ID: 15448171
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
